EUCTR2018-004464-57-ES
Active, not recruiting
Phase 1
Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke - SWIFT DIRECT
niverstiy Hospital Bern0 sites404 target enrollmentJuly 4, 2019
DrugsActilyse
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niverstiy Hospital Bern
- Enrollment
- 404
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Informed consent as documented by signature
- •\-Age \= 18 to \< 86 years
- •\-Clinical signs consistent with an acute ischaemic stroke
- •\-Neurological deficit with a NIHSS of \= 8 and \< 30
- •\-Patient is eligible for IV t\-PA
- •\-Patient is eligible for endovascular treatment/therapy
- •\-Randomization no later than 4 hours 15 minutes after stroke symptom onset and initiation of IV t\-PA must be started within 4 hours 30 minutes of stroke symptoms onset (onset time is measured from the time when the subject was last seen well)
- •\-Occlusion (mTICI 0\-1\) of the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, or both confirmed by CT or MR angiography, accessible for MT
- •\-Core\-infarct volume of ASPECTS greater than or equal to 6 (\= 6\) based on baseline CT or MRI
- •Are the trial subjects under 18? no
Exclusion Criteria
- •Acute intracranial haemorrhage
- •Any contraindication for IV t\-PA
- •Pre\-treatment with IV t\-PA
- •In\-hospital stroke
- •Pregnancy or lactating women. A negative pregnancy test before randomization is required for all women with child\-bearing potential.
- •Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys
- •Known current participation in a clinical trial
- •Renal insufficiency as defined by a serum creatinine \> 2\.0 mg/dl (or 176\.8 µmol/l) or glomerular filtration rate (GFR) \< 30 mL/min and /or known history of renal insufficiency or requirement for haemodialysis or peritoneal dialysis
- •Severe comorbid condition with life expectancy less than 90 days at baseline
- •Known advanced dementia or significant pre\-stroke disability (mRS score of \= 2\)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation StrokeAcute Anterior Circulation Ischaemic StrokeTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-004464-57-GBniverstiy Hospital Bern404
Active, not recruiting
Phase 1
Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation StrokeEUCTR2018-004464-57-ATKlinik für Neurologie, Inselspital, Universitätsspital Bern404
Active, not recruiting
Phase 1
Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation StrokeAcute Anterior Circulation StrokeTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-004464-57-DEniverstiy Hospital Bern404
Not yet recruiting
Not Applicable
An Open Label, Single Centre Clinical Trial to assess the Clinical performance of CRISPR-CAS based sensing platform Assay in detecting Breast CancerCTRI/2023/01/048792Archeron Group
Completed
Phase 3
Pun sudar thyla thiri for Pouthiram (Fistula in ano)Health Condition 1: K605- Anorectal fistulaCTRI/2023/08/056066ational Institute of SIddha20